METABOLISM OF YM155 MONOBROMIDE, A NOVEL SURVIVIN SUPPRESSANT: IN VITRO SPECIES COMPARISON AND IDENTIFICATION OF METABOLITES IN RATS

被引：0
|
作者：
Sohda, Kin-ya [1 ]
Suzuki, Katsuhiro [1 ]
Nakamura, Eiji [2 ]
Minematsu, Tsuyoshi [1 ]
Hashimoto, Tadashi [1 ]
Imai, Harumitsu [1 ]
Usui, Takashi [1 ]
Kawamura, Akio [1 ]
Kamimura, Hidetaka [1 ]
机构：
[1] Astellas Pharma Inc, Drug Metab Res Labs, Tokyo, Japan
[2] Astellas Res Serv Co Ltd, Drug Anal & Metab Res Dept, Tokyo, Japan
来源：
DRUG METABOLISM REVIEWS | 2007年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
356
引用
收藏
页码：253 / 254
页数：2
相关论文
共 50 条
  • [21] YM155: A Small Molecule Survivin Suppressant with Potent Antitumor Effect in Human Breast Cancer Models
    Kita, A.
    Nakahara, T.
    Yamanaka, K.
    Nakata, M.
    Kaneko, N.
    Koutoku, H.
    Sasamata, M.
    CANCER RESEARCH, 2009, 69 (24) : 692S - 693S
  • [22] Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
    Michaelis, Martin
    Voges, Yvonne
    Rothweiler, Florian
    Weipert, Fabian
    Zia-Ahmad, Amara
    Cinatl, Jaroslav
    von Deimling, Andreas
    Westermann, Frank
    Roedel, Franz
    Wass, Mark N.
    Cinatl, Jindrich, Jr.
    CANCERS, 2020, 12 (03)
  • [23] YM155: a small molecule survivin suppressant with potent antitumor effect in human cancer xenograft models
    Kita, Aya
    Nakahara, Takahito
    Takeuchi, Masahiro
    Kinoyama, Isao
    Matsuhisa, Akira
    Yamanaka, Kentaro
    Nakata, Mari
    Kaneko, Naoki
    Koutoku, Hiroshi
    Sasamata, Masao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 32P - 32P
  • [24] Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS
    Minoda, Masaya
    Kawamoto, Teruya
    Ueha, Takeshi
    Kamata, Etsuko
    Morishita, Masayuki
    Harada, Risa
    Toda, Mitsunori
    Onishi, Yasuo
    Hara, Hitomi
    Kurosaka, Masahiro
    Akisue, Toshihiro
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (03) : 891 - 899
  • [25] Tumor regression induced by YM155, a novel, small molecule survivin suppressant, in experimental human lung tumor models.
    Nakahara, Takahito
    Takeuchi, Masahiro
    Kinoyama, Isao
    Kita, Aya
    Yamanaka, Kentaro
    Matsuhisa, Akira
    Sasamata, Masao
    CANCER RESEARCH, 2006, 66 (08)
  • [26] Tumor regression induced by YM155, a novel, survivin suppressant, in human diffuse large B-cell lymphoma models
    Kaneko, Naoki
    Kita, Aya
    Nakahara, Takahito
    Nakata, Mari
    Koutoku, Hiroshi
    Sasamata, Masao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 260P - 260P
  • [27] Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
    Nakamura, Naoto
    Yamauchi, Tomohiro
    Hiramoto, Masashi
    Yuri, Masatoshi
    Naito, Masanori
    Takeuchi, Masahiro
    Yamanaka, Kentaro
    Kita, Aya
    Nakahara, Takahito
    Kinoyama, Isao
    Matsuhisa, Akira
    Kaneko, Naoki
    Koutoku, Hiroshi
    Sasamata, Masao
    Yokota, Hiroyuki
    Kawabata, Shigeki
    Furuichi, Kiyoshi
    MOLECULAR & CELLULAR PROTEOMICS, 2012, 11 (07)
  • [28] Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma
    Yu-Fan Wang
    Wei Zhang
    Ke-Fei He
    Bing Liu
    Lu Zhang
    Wen-Feng Zhang
    Ashok B. Kulkarni
    Yi-Fang Zhao
    Zhi-Jun Sun
    Apoptosis, 2014, 19 : 748 - 758
  • [29] YM155, a novel small molecule survivin suppressant, exhibits curative antitumor activities in experimental human malignant lymphoma models in vivo
    Kita, A.
    Nakahara, T.
    Yamanaka, K.
    Koutoku, H.
    Takeuchi, M.
    Kinoyama, I.
    Matsuhisa, A.
    Sasamata, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 116 - 116
  • [30] Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma
    Wang, Yu-Fan
    Zhang, Wei
    He, Ke-Fei
    Liu, Bing
    Zhang, Lu
    Zhang, Wen-Feng
    Kulkarni, Ashok B.
    Zhao, Yi-Fang
    Sun, Zhi-Jun
    APOPTOSIS, 2014, 19 (04) : 748 - 758
12345